nach oben

Brain Tumor Pathology

Erschienen in:

31.01.2022 | Review Article

Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas

verfasst von: Hideyuki Arita, Koichi Ichimura

Erschienen in: Brain Tumor Pathology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

TERT promoter mutations are one of the most common genetic alterations in adult-type diffuse gliomas and show specific patterns compared with other genetic alterations according to glioma subtypes. This mutation has variable impacts on patient outcomes in association with other genetic alterations, including IDH1/2 mutations or histological types. The purpose of this paper is to review the current knowledge on the values of TERT promoter mutations in the diagnosis and prognostication of adult-type diffuse gliomas. We also aimed to discuss the interaction between the prognostic impacts of TERT promoter mutations and other molecular alterations. Although its impact on prognosis is somewhat complicated and enigmatic, the mutational status of the TERT promoter provides highly useful information for predicting patients’ outcomes in the conventional classification of gliomas defined by IDH1/2 and 1p/19q status.

Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. https://doi.org/10.1093/neuonc/noab106CrossRefPubMed

Horn S, Figl A, Rachakonda PS et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:959–961. https://doi.org/10.1126/science.1230062CrossRefPubMed

Huang FW, Hodis E, Xu MJ et al (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339:957–959. https://doi.org/10.1126/science.1229259CrossRefPubMedPubMedCentral

Koelsche C, Sahm F, Capper D et al (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. https://doi.org/10.1007/s00401-013-1195-5CrossRefPubMedPubMedCentral

Arita H, Narita Y, Fukushima S et al (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126:267–276. https://doi.org/10.1007/s00401-013-1141-6CrossRefPubMed

Killela PJ, Reitman ZJ, Jiao Y et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110:6021–6026. https://doi.org/10.1073/pnas.1303607110CrossRefPubMedPubMedCentral

Remke M, Ramaswamy V, Peacock J et al (2013) TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. https://doi.org/10.1007/s00401-013-1198-2CrossRefPubMedPubMedCentral

Sahm F, Schrimpf D, Olar A et al (2016) TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv377CrossRefPubMed

Arita H, Yamasaki K, Matsushita Y et al (2016) A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 4:79. https://doi.org/10.1186/s40478-016-0351-2CrossRefPubMedPubMedCentral

10.

Labussiere M, Di Stefano AL, Gleize V et al (2014) TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer 111:2024–2032. https://doi.org/10.1038/bjc.2014.538CrossRefPubMedPubMedCentral

11.

Lee J, Putnam AR, Chesier SH et al (2018) Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts. Acta Neuropathol Commun 6:95. https://doi.org/10.1186/s40478-018-0598-xCrossRefPubMedPubMedCentral

12.

Nguyen HN, Lie A, Li T et al (2016) Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro Oncol. https://doi.org/10.1093/neuonc/now189CrossRefPubMedCentral

13.

Nonoguchi N, Ohta T, Oh JE et al (2013) TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 126:931–937. https://doi.org/10.1007/s00401-013-1163-0CrossRefPubMed

14.

Simon M, Hosen I, Gousias K et al (2015) TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol 17:45–52. https://doi.org/10.1093/neuonc/nou158CrossRefPubMed

15.

Spiegl-Kreinecker S, Lotsch D, Ghanim B et al (2015) Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro Oncol 17:1231–1240. https://doi.org/10.1093/neuonc/nov010CrossRefPubMedPubMedCentral

16.

Kikuchi Z, Shibahara I, Yamaki T et al (2020) TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma. Neurooncol Adv 2:vdaa114. https://doi.org/10.1093/noajnl/vdaa114CrossRefPubMedPubMedCentral

17.

Shu C, Wang Q, Yan X et al (2018) The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival. Cancer Med 7:3704–3712. https://doi.org/10.1002/cam4.1666CrossRefPubMedPubMedCentral

18.

Bell RJ, Rube HT, Kreig A et al (2015) Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348:1036–1039. https://doi.org/10.1126/science.aab0015CrossRefPubMedPubMedCentral

19.

Pierini T, Nardelli C, Lema Fernandez AG et al (2020) New somatic TERT promoter variants enhance the telomerase activity in glioblastoma. Acta Neuropathol Commun 8:145. https://doi.org/10.1186/s40478-020-01022-4CrossRefPubMedPubMedCentral

20.

Barthel FP, Wei W, Tang M et al (2017) Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet 49:349–357. https://doi.org/10.1038/ng.3781CrossRefPubMedPubMedCentral

21.

Castelo-Branco P, Choufani S, Mack S et al (2013) Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol 14:534–542. https://doi.org/10.1016/S1470-2045(13)70110-4CrossRefPubMed

22.

Lee DD, Leao R, Komosa M et al (2019) DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. J Clin Invest 129:223–229. https://doi.org/10.1172/JCI121303CrossRefPubMed

23.

Adachi JI, Shirahata M, Suzuki T et al (2021) Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma. Brain Tumor Pathol 38:201–209. https://doi.org/10.1007/s10014-021-00403-4CrossRefPubMed

24.

Ichimura K (2019) TERT promoter mutation as a diagnostic marker for diffuse gliomas. Neuro Oncol 21:417–418. https://doi.org/10.1093/neuonc/noz025CrossRefPubMedPubMedCentral

25.

Brennan CW, Verhaak RG, McKenna A et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477. https://doi.org/10.1016/j.cell.2013.09.034CrossRefPubMedPubMedCentral

26.

Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468. https://doi.org/10.1038/ng.3273CrossRefPubMed

27.

Higa N, Akahane T, Yokoyama S et al (2020) A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas. Cancer Sci 111:3902–3911. https://doi.org/10.1111/cas.14597CrossRefPubMedPubMedCentral

28.

Miki S, Satomi K, Ohno M et al (2020) Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR. Brain Tumor Pathol 37:154–158. https://doi.org/10.1007/s10014-020-00375-xCrossRefPubMed

29.

Fontanilles M, Marguet F, Beaussire L et al (2020) Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma. Acta Neuropathol Commun 8:179. https://doi.org/10.1186/s40478-020-01057-7CrossRefPubMedPubMedCentral

30.

Diplas BH, Liu H, Yang R et al (2019) Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas. Neuro Oncol 21:440–450. https://doi.org/10.1093/neuonc/noy167CrossRefPubMed

31.

Arita H, Matsushita Y, Machida R et al (2020) TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Acta Neuropathol Commun 8:201. https://doi.org/10.1186/s40478-020-01078-2CrossRefPubMedPubMedCentral

32.

Tesileanu CMS, Dirven L, Wijnenga MMJ et al (2020) Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol 22:515–523. https://doi.org/10.1093/neuonc/noz200CrossRefPubMed

33.

Stichel D, Ebrahimi A, Reuss D et al (2018) Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136:793–803. https://doi.org/10.1007/s00401-018-1905-0CrossRefPubMed

34.

Fujimoto K, Arita H, Satomi K et al (2021) TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathol 142:323–338. https://doi.org/10.1007/s00401-021-02337-9CrossRefPubMed

35.

Gomes I, Moreno DA, Dos Reis MB et al (2021) Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide. J Neurooncol 151:135–144. https://doi.org/10.1007/s11060-020-03675-6CrossRefPubMed

36.

Labussiere M, Boisselier B, Mokhtari K et al (2014) Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology 83:1200–1206. https://doi.org/10.1212/WNL.0000000000000814CrossRefPubMed

37.

Gramatzki D, Felsberg J, Hentschel B et al (2021) Telomerase reverse transcriptase promoter mutation- and O(6)-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link? Eur J Cancer 147:84–94. https://doi.org/10.1016/j.ejca.2021.01.014CrossRefPubMed

38.

Mosrati MA, Malmstrom A, Lysiak M et al (2015) TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget 6:16663–16673. https://doi.org/10.18632/oncotarget.4389CrossRefPubMedPubMedCentral

39.

Killela PJ, Pirozzi CJ, Healy P et al (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5:1515–1525CrossRef

40.

Umehara T, Arita H, Yoshioka E et al (2019) Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts. Acta Neuropathol Commun 7:15. https://doi.org/10.1186/s40478-019-0749-8CrossRefPubMedCentral

41.

Lee Y, Koh J, Kim SI et al (2017) The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. Acta Neuropathol Commun 5:62. https://doi.org/10.1186/s40478-017-0465-1CrossRefPubMedPubMedCentral

42.

Barthel FP, Wesseling P, Verhaak RGW (2018) Reconstructing the molecular life history of gliomas. Acta Neuropathol 135:649–670. https://doi.org/10.1007/s00401-018-1842-yCrossRefPubMedPubMedCentral

43.

Akyerli CB, Yuksel S, Can O et al (2018) Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. J Neurosurg 128:1102–1114. https://doi.org/10.3171/2016.11.JNS16973CrossRefPubMed

44.

Zhang Z, Chan AK, Ding X et al (2017) Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas. Neuro Oncol 19:1008–1010. https://doi.org/10.1093/neuonc/nox042CrossRefPubMedPubMedCentral

45.

Korber V, Yang J, Barah P et al (2019) Evolutionary Trajectories of IDH(WT) glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis. Cancer Cell 35:692-704 e612. https://doi.org/10.1016/j.ccell.2019.02.007CrossRefPubMed

46.

Batista R, Cruvinel-Carloni A, Vinagre J et al (2016) The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. Int J Cancer 139:414–423. https://doi.org/10.1002/ijc.30057CrossRefPubMed

47.

Pekmezci M, Rice T, Molinaro AM et al (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001–1016. https://doi.org/10.1007/s00401-017-1690-1CrossRefPubMedPubMedCentral

48.

Fukai J, Arita H, Umehara T et al (2020) Molecular characteristics and clinical outcomes of elderly patients with IDH-wildtype glioblastomas: comparative study of older and younger cases in Kansai Network cohort. Brain Tumor Pathol 37:50–59. https://doi.org/10.1007/s10014-020-00363-1CrossRefPubMed

49.

Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. https://doi.org/10.1056/NEJMoa043331CrossRefPubMed

50.

Hsu CP, Hsu NY, Lee LW et al (2006) Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter–effect on telomerase expression and telomere length maintenance in non-small cell lung cancer. Eur J Cancer 42:1466–1474. https://doi.org/10.1016/j.ejca.2006.02.014CrossRefPubMed

51.

Nencha U, Rahimian A, Giry M et al (2016) TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas. J Neurooncol 126:441–446. https://doi.org/10.1007/s11060-015-1999-3CrossRefPubMed

52.

Aoki K, Nakamura H, Suzuki H et al (2017) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. https://doi.org/10.1093/neuonc/nox132CrossRefPubMedCentral

53.

Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508. https://doi.org/10.1056/NEJMoa1407279CrossRefPubMedPubMedCentral

54.

Wijnenga MMJ, Dubbink HJ, French PJ et al (2017) Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol 134:957–959. https://doi.org/10.1007/s00401-017-1781-zCrossRefPubMed

55.

Brat DJ, Aldape K, Colman H et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol 136:805–810. https://doi.org/10.1007/s00401-018-1913-0CrossRefPubMedPubMedCentral

56.

Berzero G, Di Stefano AL, Ronchi S et al (2021) IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro Oncol 23:955–966. https://doi.org/10.1093/neuonc/noaa258CrossRefPubMed

57.

Maida Y, Yasukawa M, Okamoto N et al (2014) Involvement of telomerase reverse transcriptase in heterochromatin maintenance. Mol Cell Biol 34:1576–1593. https://doi.org/10.1128/MCB.00093-14CrossRefPubMedPubMedCentral

Titel: Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas
verfasst von: Hideyuki Arita
Koichi Ichimura
Publikationsdatum: 31.01.2022
Verlag: Springer Nature Singapore
Erschienen in: Brain Tumor Pathology / Ausgabe 3/2022
Print ISSN: 1433-7398
Elektronische ISSN: 1861-387X
DOI: https://doi.org/10.1007/s10014-021-00424-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation

Molecular subgrouping of ependymoma across three anatomic sites and their prognostic implications

Timing of H3K27me3 loss in secondary anaplastic meningiomas

Diffusely infiltrating glioma with CREBBP–BCORL1 fusion showing overexpression of not only BCORL1 but BCOR: A case report

Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group